Cover Image
Market Research Report
Product code 
989594

Thrombocytopenia - Epidemiology Forecast to 2030

Published: Pre-Order | DelveInsight Business Research LLP | 100 Pages | Delivery time: 2-10 business days

Price

Back to Top
Thrombocytopenia - Epidemiology Forecast to 2030
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 100 Pages
Delivery time: 2-10 business days
  • ALL
  • Description
  • Table of Contents
Description

DelveInsight's 'Thrombocytopenia-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted Thrombocytopenia epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

Thrombocytopenia Understanding

Thrombocytopenia is a condition in which the blood has a lower than a normal number of blood cell fragments called platelets. Platelets are made in the bone marrow along with other kinds of blood cells. They travel through the blood vessels and stick together (clot) to stop any bleeding that may happen if a blood vessel is damaged. Platelets also are called thrombocytes because a clot also is called a thrombus. When a patient's blood has too few platelets, mild to serious bleeding can occur. Bleeding can occur inside the body (internal bleeding) or underneath the skin, or from the skin's surface (external bleeding). A normal platelet count in adults ranges from 150,000 to 450,000 platelets/μL of blood. A platelet count of fewer than 150,000 platelets/μL is lower than normal. If the blood platelet count falls below normal, the patient has thrombocytopenia. However, the risk for serious bleeding does not occur until the count becomes very low-less than 10,000 or 20,000 platelets/μL. Mild bleeding sometimes occurs when the count is less than 50,000 platelets per microliter.

Many factors can cause thrombocytopenia (a low platelet count). The condition can be inherited or acquired. "Inherited" means parents pass the gene for the condition to the patient. "Acquired" means the patients are not born with the condition, but they develop it. Sometimes the cause of thrombocytopenia is not known.

Thrombocytopenia Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia and Total Cases of Thrombocytopenia scenario of Thrombocytopenia in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030.

Thrombocytopenia Detailed Epidemiology Segmentation

  • As per DelveInsight analysis, the total number of cases of Thrombocytopenia in the 7MM was 1,653,934 in 2020. These cases of Thrombocytopenia in the 7MM are expected to increase throughout the study period i.e. 2018-2030, with CAGR of 0.66% for the study period 2018-2030.
  • As per DelveInsight analysis, the United States accounted for the highest number of Thrombocytopenia cases among the 7MM. The total number of Thrombocytopenia cases in the US was estimated to be 467,078 in 2020.
  • In 2020, the prevalent population of Thrombotic Thrombocytopenia in the United States was 6,002 which are expected to rise with the CAGR of 0.79% for the study period 2018-2030.
  • In 2020, there were 66,708 prevalent cases of Immune thrombocytopenia (ITP) in the United States.
  • Germany ranked second-highest for Thrombocytopenia cases among 7MM. In 2020, Germany had 325,202 Thrombocytopenia cases.
  • Among the European 5 countries, Germany had the highest cases of Thrombocytopenia with 325,202 cases, followed by the United Kingdom and Spain, with 230,597 cases and 182,796 cases, respectively. On the other hand, Italy had the lowest cases, i.e., 102,933 in 2020.
  • As per DelveInsight analysis, Japan accounted for the fourth-highest number of Thrombocytopenia cases among the 7MM. The total number of Thrombocytopenia cases in Japan was estimated to be 219,017 in 2020.

Scope of the Report:

  • The report covers the descriptive overview of Thrombocytopenia, explaining its causes, symptoms, and diagnosis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP), Prevalent Cases of Immune Thrombocytopenia (ITP), Prevalent Cases of Thrombocytopenia in Chronic Liver Disease, Incident Cases of Chemotherapy-induced Thrombocytopenia, Number of Cases of Heparin-induced Thrombocytopenia, and Total Cases of Thrombocytopenia.

Report Highlights:

  • 10-Year Forecast of Thrombocytopenia
  • 7MM Coverage
  • Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP)
  • Prevalent Cases of Immune Thrombocytopenia (ITP)
  • Prevalent Cases of Thrombocytopenia in Chronic Liver Disease
  • Incident Cases of Chemotherapy-induced Thrombocytopenia
  • Number of Cases of Heparin-induced Thrombocytopenia
  • Total Cases of Thrombocytopenia

Key Questions Answered

  • What are the disease risk, burden, and unmet needs of Thrombocytopenia?
  • What is the historical Thrombocytopenia patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Thrombocytopenia at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Thrombocytopenia?
  • Out of the countries mentioned above, which country would have the highest patient population of Thrombocytopenia during the forecast period (2021-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021-2030)?

Reasons to buy:

The Thrombocytopenia report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Thrombocytopenia market.
  • Quantify patient populations in the 7MM Thrombocytopenia market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the specific type of Thrombocytopenia that presents the best opportunities for Thrombocytopenia therapeutics in each of the markets covered.
  • The Thrombocytopenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Thrombocytopenia epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018-2030

Table of Contents
Product Code: DIEI0229

Table of Contents

1 Key Insights

2 Executive Summary of Thrombocytopenia

3 Thrombocytopenia Epidemiology Overview at a Glance

  • 3.1. Epidemiology Share (%) Distribution of Thrombocytopenia in 2018
  • 3.2. Epidemiology Share (%) Distribution of Thrombocytopenia in 2030

4 Thrombocytopenia: Disease Background and Overview

  • 4.1. Introduction
  • 4.2. Causes of Thrombocytopenia
    • 4.2.1. Emergent Thrombocytopenia
    • 4.2.2. Non-emergent Thrombocytopenia
  • 4.3. Symptoms of Thrombocytopenia
  • 4.4. Diagnosis of Thrombocytopenia
    • 4.4.1. Chemotherapy-induced thrombocytopenia (CIT)
    • 4.4.2. Immune thrombocytopenic purpura
    • 4.4.3. Heparin-induced Thrombocytopenia
    • 4.4.4. Thrombocytopenia associated with Chronic Liver
    • 4.4.5. Thrombotic thrombocytopenic purpura
  • 4.5. Diagnostic Guidelines of Thrombocytopenia
    • 4.5.1. Clinical Practice Guideline on the Evaluation and Management of Immune Thrombocytopenia (ITP)
    • 4.5.2. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura (TTP)
    • 4.5.3. Guidelines on the diagnosis of heparin-induced thrombocytopenia (HIT): second edition

5 Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Epidemiology Methodology
  • 5.3. 7MM Total Prevalent Patient Population of Thrombocytopenia

6 Country Wise-Epidemiology of Thrombocytopenia

  • 6.1 United States Epidemiology
    • 6.1.1 Assumptions and Rationale
    • 6.1.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura (TTP) in the United States
    • 6.1.3 Prevalent Cases of Immune Thrombocytopenia (ITP) in the United States
    • 6.1.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the United States
    • 6.1.5 Incident Cases of Chemotherapy-induced Thrombocytopenia in the United States
    • 6.1.6 Number of Cases of Heparin-induced Thrombocytopenia in the United States
    • 6.1.7 Total Cases of Thrombocytopenia in the United States
  • 6.2 EU5 Epidemiology
    • 6.2.1 Germany
      • 6.2.1.1 Assumptions and Rationale
      • 6.2.1.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Germany
      • 6.2.1.3 Prevalent Cases of Immune Thrombocytopenia in Germany
      • 6.2.1.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Germany
      • 6.2.1.5 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Germany
      • 6.2.1.6 Number of Cases of Heparin-induced Thrombocytopenia in Germany
      • 6.2.1.7 Total Cases of Thrombocytopenia in Germany
    • 6.2.2 France
      • 6.2.2.1 Assumptions and Rationale
      • 6.2.2.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in France
      • 6.2.2.3 Prevalent Cases of Immune Thrombocytopenia in France
      • 6.2.2.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in France
      • 6.2.2.5 Incidence Cases of Chemotherapy-induced Thrombocytopenia in France
      • 6.2.2.6 Number of Cases of Heparin-induced Thrombocytopenia in France
      • 6.2.2.7 Total Cases of Thrombocytopenia in France
    • 6.2.3 Italy
      • 6.2.3.1 Assumptions and Rationale
      • 6.2.3.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Italy
      • 6.2.3.3 Prevalent Cases of Immune Thrombocytopenia in Italy
      • 6.2.3.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Italy
      • 6.2.3.5 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Italy
      • 6.2.3.6 Number of Cases of Heparin-induced Thrombocytopenia in Italy
      • 6.2.3.7 Total Cases of Thrombocytopenia in Italy
    • 6.2.4 Spain
      • 6.2.4.1 Assumptions and Rationale
      • 6.2.4.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Spain
      • 6.2.4.3 Prevalent Cases of Immune Thrombocytopenia in Spain
      • 6.2.4.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Spain
      • 6.2.4.5 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Spain
      • 6.2.4.6 Number of Cases of Heparin-induced Thrombocytopenia in Spain
      • 6.2.4.7 Total Cases of Thrombocytopenia in Spain
    • 6.2.5 United Kingdom
      • 6.2.5.1 Assumptions and Rationale
      • 6.2.5.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the UK
      • 6.2.5.3 Prevalent Cases of Immune Thrombocytopenia in the UK
      • 6.2.5.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the UK
      • 6.2.5.5 Incidence Cases of Chemotherapy-induced Thrombocytopenia in the UK
      • 6.2.5.6 Number of Cases of Heparin-induced Thrombocytopenia in the UK
      • 6.2.5.7 Total Cases of Thrombocytopenia in the UK
  • 6.3 Japan Epidemiology
    • 6.3.1 Assumptions and Rationale
    • 6.3.2 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Japan
    • 6.3.3 Prevalent Cases of Immune Thrombocytopenia in Japan
    • 6.3.4 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Japan
    • 6.3.5 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Japan
    • 6.3.6 Number of Cases of Heparin-induced Thrombocytopenia in Japan
    • 6.3.7 Total Cases of Thrombocytopenia in Japan

7 Appendix

  • 7.1. Bibliography
  • 7.2. Report Methodology

8 DelveInsight Capabilities

9 Disclaimer

10 About DelveInsight

List of Tables

  • Table 1 Summary of Thrombocytopenia, Epidemiology, and Key Events (2018-2030)
  • Table 2 Differential diagnosis of thrombocytopenia according to the clinical scenario
  • Table 3 Total Prevalent Patient Population of Thrombocytopenia in the 7MM (2018-2030)
  • Table 4 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the United States (2018-2030)
  • Table 5 Prevalent Cases of Immune Thrombocytopenia in the United States (2018-2030)
  • Table 6 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the United States (2018-2030)
  • Table 7 Incident Cases of Chemotherapy-induced Thrombocytopenia in the United States (2018-2030)
  • Table 8 Number of Cases of Heparin-induced Thrombocytopenia in the United States (2018-2030)
  • Table 9 Total Cases of Thrombocytopenia in the United States (2018-2030)
  • Table 10 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Germany (2018-2030)
  • Table 11 Prevalent Cases of Immune Thrombocytopenia in Germany (2018-2030)
  • Table 12 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Germany (2018-2030)
  • Table 13 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Germany (2018-2030)
  • Table 14 Number of Cases of Heparin-induced Thrombocytopenia in Germany (2018-2030)
  • Table 15 Total Cases of Thrombocytopenia in Germany (2018-2030)
  • Table 16 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in France (2018-2030)
  • Table 17 Prevalent Cases of Immune Thrombocytopenia in France (2018-2030)
  • Table 18 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in France (2018-2030)
  • Table 19 Incidence Cases of Chemotherapy-induced Thrombocytopenia in France (2018-2030)
  • Table 20 Number of Cases of Heparin-induced Thrombocytopenia in France (2018-2030)
  • Table 21 Total Cases of Thrombocytopenia in France (2018-2030)
  • Table 22 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Italy (2018-2030)
  • Table 23 Prevalent Cases of Immune Thrombocytopenia in Italy (2018-2030)
  • Table 24 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Italy (2018-2030)
  • Table 25 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Italy (2018-2030)
  • Table 26 Number of Cases of Heparin-induced Thrombocytopenia in Italy (2018-2030)
  • Table 27 Total Cases of Thrombocytopenia in Italy (2018-2030)
  • Table 28 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Spain (2018-2030)
  • Table 29 Prevalent Cases of Immune Thrombocytopenia in Spain (2018-2030)
  • Table 30 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Spain (2018-2030)
  • Table 31 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Spain (2018-2030)
  • Table 32 Number of Cases of Heparin-induced Thrombocytopenia in Spain (2018-2030)
  • Table 33 Total Cases of Thrombocytopenia in Spain (2018-2030)
  • Table 34 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the UK (2018-2030)
  • Table 35 Prevalent Cases of Immune Thrombocytopenia in the UK (2018-2030)
  • Table 36 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the UK (2018-2030)
  • Table 37 Incidence Cases of Chemotherapy-induced Thrombocytopenia in the UK (2018-2030)
  • Table 38 Number of Cases of Heparin-induced Thrombocytopenia in the UK (2018-2030)
  • Table 39 Total Cases of Thrombocytopenia in the UK (2018-2030)
  • Table 40 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Japan (2018-2030)
  • Table 41 Prevalent Cases of Immune Thrombocytopenia in Japan (2018-2030)
  • Table 42 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Japan (2018-2030)
  • Table 43 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Japan (2018-2030)
  • Table 44 Number of Cases of Heparin-induced Thrombocytopenia in Japan (2018-2030)
  • Table 45 Total Cases of Thrombocytopenia in Japan (2018-2030)

List of Figures

  • Figure 1 Etiology of thrombocytopenia
  • Figure 2 Cellular pathogenic mechanisms in immune thrombocytopenia (ITP)
  • Figure 3 Thrombocytopenia: diagnostic algorithm starting with the complete blood count (CBC)
  • Figure 4 Diagnostic Algorithm to Confirm or Rule Out Heparin-Induced Thrombocytopenia (HIT) in Patients Who Have Not Undergone Bypass Surgery
  • Figure 5 General approach and mechanism to the diagnosis of thrombocytopenia in liver disease
  • Figure 6 Flow chart for ADAMTS13 laboratory investigation in thrombotic thrombocytopenic purpura
  • Figure 7 Total Prevalent Patient Population of Thrombocytopenia in the 7MM (2018-2030)
  • Figure 8 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the United States (2018-2030)
  • Figure 9 Prevalent Cases of Immune Thrombocytopenia in the United States (2018-2030)
  • Figure 10 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the United States (2018-2030)
  • Figure 11 Incident Cases of Chemotherapy-induced Thrombocytopenia in the United States (2018-2030)
  • Figure 12 Number of Cases of Heparin-induced Thrombocytopenia in the United States (2018-2030)
  • Figure 13 Total Cases of Thrombocytopenia in the United States (2018-2030)
  • Figure 14 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Germany (2018-2030)
  • Figure 15 Prevalent Cases of Immune Thrombocytopenia in Germany (2018-2030)
  • Figure 16 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Germany (2018-2030)
  • Figure 17 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Germany (2018-2030)
  • Figure 18 Number of Cases of Heparin-induced Thrombocytopenia in Germany (2018-2030)
  • Figure 19 Total Cases of Thrombocytopenia in Germany (2018-2030)
  • Figure 20 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in France (2018-2030)
  • Figure 21 Prevalent Cases of Immune Thrombocytopenia in France (2018-2030)
  • Figure 22 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in France (2018-2030)
  • Figure 23 Incidence Cases of Chemotherapy-induced Thrombocytopenia in France (2018-2030)
  • Figure 24 Number of Cases of Heparin-induced Thrombocytopenia in France (2018-2030)
  • Figure 25 Total Cases of Thrombocytopenia in France (2018-2030)
  • Figure 26 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Italy (2018-2030)
  • Figure 27 Prevalent Cases of Immune Thrombocytopenia in Italy (2018-2030)
  • Figure 28 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Italy (2018-2030)
  • Figure 29 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Italy (2018-2030)
  • Figure 30 Number of Cases of Heparin-induced Thrombocytopenia in Italy (2018-2030)
  • Figure 31 Total Cases of Thrombocytopenia in Italy (2018-2030)
  • Figure 32 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Spain (2018-2030)
  • Figure 33 Prevalent Cases of Immune Thrombocytopenia in Spain (2018-2030)
  • Figure 34 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Spain (2018-2030)
  • Figure 35 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Spain (2018-2030)
  • Figure 36 Number of Cases of Heparin-induced Thrombocytopenia in Spain (2018-2030)
  • Figure 37 Total Cases of Thrombocytopenia in Spain (2018-2030)
  • Figure 38 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in the UK (2018-2030)
  • Figure 39 Prevalent Cases of Immune Thrombocytopenia in the UK (2018-2030)
  • Figure 40 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in the UK (2018-2030)
  • Figure 41 Incidence Cases of Chemotherapy-induced Thrombocytopenia in the UK (2018-2030)
  • Figure 42 Number of Cases of Heparin-induced Thrombocytopenia in the UK (2018-2030)
  • Figure 43 Total Cases of Thrombocytopenia in the UK (2018-2030)
  • Figure 44 Prevalent Cases of Thrombotic Thrombocytopenic Purpura in Japan (2018-2030)
  • Figure 45 Prevalent Cases of Immune Thrombocytopenia in Japan (2018-2030)
  • Figure 46 Prevalent Cases of Thrombocytopenia in Chronic Liver Disease in Japan (2018-2030)
  • Figure 47 Incidence Cases of Chemotherapy-induced Thrombocytopenia in Japan (2018-2030)
  • Figure 48 Number of Cases of Heparin-induced Thrombocytopenia in Japan (2018-2030)
  • Figure 49 Total Cases of Thrombocytopenia in Japan (2018-2030)